clinical trial · NCT00992238
A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions
HealthyFlavoxate Hydrochloride Tablets, 100mgUrispas® Tablets, 100mg
brief summary
The purpose of this study is to compare the relative bioavailability of Flavoxate Hydrochloride tablets 100mg manufactured by Paddock Laboratories, Inc., with that of Urispas® tablets 100mg by SmithKline Beecham Pharmaceuticals under fasting conditions.
started
—
primary completion
—
completion
—
last updated
Jul 10, 2023
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol